×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
PR Newswire
PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and...
2 months ago
FDA Approves Fabry Disease Treatment from Chiesi, Protalix
BioSpace
Elfabrio's label contains a boxed warning for hypersensitivity reactions, such as anaphylaxis, and recommends that medical support measures...
12 months ago
FDA Rejects Quick Approval of PRX-102, Plant-based ERT for Fabry
Fabry Disease News
Protalix and Chiesi are weighing steps for PRX-102 (pegunigalsidase alfa), for adults with Fabry, after FDA said no to accelerated approval.
36 months ago
Protalix, Chiesi win US go-ahead for Elfabrio in Fabry disease
BioWorld MedTech
On the heels of the marketing OK in Europe, Protalix Biotherapeutics Inc. and the Chiesi Group's global rare diseases unit scored approval...
12 months ago
Protalix Biotherapeutics: Is It Worth The Wait? (NYSE:PLX)
Seeking Alpha
Protalix concluded its Type A meeting with the US FDA, providing a way forward with its lead indication PRX-102. Check out why I'm bullish...
28 months ago
Protalix shares jump on progress of pegunigalsidase alfa
The Pharma Letter
Israeli drugmaker Protalix BioTherapeutics closed 40% up on Monday amid good news for pegunigalsidase alfa, the Fabry disease candidate that...
54 months ago
As Fabry push with Protalix continues, FDA says yes to Chiesi's Lamzede ERT for alpha-mannosidosis
BioWorld MedTech
Chiesi Farmaceutici SpA scored U.S. FDA clearance of the enzyme replacement therapy (ERT) Lamzede (velmanase alfa-tycv) for non-central...
15 months ago
Protalix Announces Strategy for Novel CF Drug AIR DNase for...
Cystic Fibrosis News Today
Read about Protalix Biotherapeutics' plans to further develop AIR DNase for recurrent respiratory infection in cystic fibrosis.
112 months ago
The Prognosis For Protalix BioTherapeutics Stock (NYSE:PLX)
Seeking Alpha
Protalix BioTherapeutics has rallied after its Fabry disease asset PLX-102 received a PDUFA date from the FDA. Here's a full investment...
15 months ago
FDA Action Alert: Sarepta, Protalix, Otsuka/Lundbeck and More
BioSpace
The FDA's agenda includes an advisory committee meeting for Sarepta's delandistrogene moxeparvovec, which, if approved, would become the...
12 months ago